Alumis Says Phase 3 Data From Plaque Psoriasis Program Reiterate Treatment's Potential as 'Leading' Oral Therapy

MT newswire2026/10/09 08:40

04:40 AM EDT, 10/09/2026 (MT Newswires) -- Alumis (ALMS) reported new envudeucitinib data from a Phase 3 clinical program that "reinforce" envudeucitinib's potential to become a "leading" oral therapy for patients with moderate-to-severe plaque psoriasis. New data include a 54% Psoriasis Area and Severity Index 100 response rate, which, the company said early Friday, is the highest publicly reported among existing and investigational oral psoriasis therapies. The cut-off was at Week 48. The data showed "early and durable improvements" in scalp disease severity, itch resolution, and quality-of-life measures, according to the company statement. Alumis said the "consistency" of these findings across the program, alongside high-threshold skin clearance and a favorable tolerability profile, is "highly encouraging and underscores the clinical relevance" of the treatment.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Swiss Franc weakens as Fed hawkish outlook lifts USD/CHF

FXStreet•2026/11/09 05:45

Sun Machinery CEO Park Kyung-hee Raises Stake to 8.40% From 8.31%

Bitget•2026/11/09 05:37

The central bank has increased its gold reserves for 24 consecutive months, with October’s increase hitting a record high for the period.

新浪财经•2026/11/09 05:37

Trader Gu Jingci: November 9 Bitcoin/Ethereum Trading Strategy and Market Analysis

AiCoin•2026/11/09 05:35